Dana-Farber Cancer Institute – Multiple Myeloma in Relapse

Access Program Information

Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are
currently participating in a clinical trial which is closing. This research study is
studying Ulocuplumab as a possible treatment. It’s an expanded access from NCT01359657